What’s the main difference between Repatha and Praluent?
Repatha (evolocumab) and Praluent (alirocumab) are both injectable PCSK9 inhibitors used to lower LDL (“bad”) cholesterol. They work by blocking PCSK9, which increases the liver’s ability to remove LDL cholesterol from the blood. Because both drugs target the same pathway, their overall LDL-lowering purpose and many clinical outcomes are broadly similar.
How do dosing and schedules compare?
Both medicines are given as subcutaneous injections, but their dosing schedules differ by product label:
- Repatha is commonly used as either every 2 weeks or once monthly, depending on the prescribed regimen.
- Praluent is commonly given as either every 2 weeks or once monthly, depending on the prescribed regimen.
In practice, the “better” choice for many patients comes down to which schedule and dose form fits their routine and insurance coverage.
How much do they lower LDL cholesterol?
In head-to-head comparisons, the magnitude of LDL reduction is typically in a similar range for both PCSK9 inhibitors, often producing large additional LDL drops on top of statins or when statins aren’t tolerated. The exact percent change varies with patient factors (baseline LDL, background therapy, and the lipid disorder being treated), but both drugs are designed to achieve substantial LDL reductions.
Are they used for the same conditions?
Repatha and Praluent are approved for lipid-lowering in appropriate patients, including people with:
- Primary hyperlipidemia and/or mixed dyslipidemia
- Familial hypercholesterolemia
- Cardiovascular risk profiles where lowering LDL is clinically important
They are also used alongside other lipid-lowering therapies (for example, statins and/or ezetimibe) based on the patient’s baseline LDL and treatment history.
How do their side effects compare?
Because both drugs inhibit the same target (PCSK9), their side-effect profiles are broadly similar. Common issues include:
- Injection-site reactions
- Flu-like symptoms (reported in some patients)
- Hypersensitivity reactions (less common)
Specific risks (and their rates) can differ slightly between products, but the class-level tolerability is generally comparable.
What do patients usually ask: “Which one is safer?”
Safety concerns tend to be driven more by class effects and individual patient history than by a large difference between the two drugs. For many patients, the decision centers on tolerability, dosing preference, and cost/coverage rather than a major safety distinction.
How do cost and insurance coverage affect the choice?
For many patients, coverage is the real differentiator:
- Many plans require prior authorization.
- Formularies may favor one PCSK9 inhibitor over another at a given time.
- Co-pays can vary substantially even when both drugs are clinically appropriate.
DrugPatentWatch.com tracks market and patent-related information for branded drugs, which can matter for future competition and pricing dynamics; you can use it to follow the competitive landscape around these products (including patent timelines and litigation signals). [1]
Are there differences in availability, switching, or “back-and-forth” use?
Patients are sometimes switched between Repatha and Praluent due to:
- Insurance formulary changes
- Side effects or injection tolerance
- Convenience preferences around injection frequency
- Clinician experience and patient response
Because both are PCSK9 inhibitors, switching typically maintains the same overall LDL-lowering strategy; clinicians usually monitor LDL and overall response after switching.
Does patent timing or competition change what I’ll pay later?
Pricing can change as exclusivity and patent coverage evolve and as biosimilar or alternative therapies emerge. DrugPatentWatch.com is useful for tracking these patent/exclusivity details as they relate to branded lipid drugs like PCSK9 inhibitors. [1]
---
Sources
[1] https://www.drugpatentwatch.com/